雷贝拉唑三联疗法治疗消化性溃疡的疗效观察

目的观察雷贝拉唑三联疗法治疗消化性溃疡的临床疗效。方法将92例消化性溃疡患者随机分为治疗组和对照组各46例。治疗组先给予雷贝拉唑10mg、阿莫西林1.0g、克拉霉素500mg;对照组先给予奥美拉唑20mg、阿莫西林1.0g、克拉霉素500mg,2组均每天2次,饭前1h服用,连服7d。然后治疗组单独给予雷贝拉唑10mg,对照组单纯给予奥美拉唑20mg,2组均每天1次,连服7d。治疗后比较2组溃疡愈合率、幽门螺杆菌(Hp)根除率,并观察2组不良反应发生情况。结果治疗组溃疡愈合率为91.30%高于对照组的60.04%,差异有统计学意义(P<0.01)。2组不良反应均轻微,可自行消失。结论雷贝拉唑三联疗法是一种短程、高效、安全的根除Hp及促进溃疡愈合的方案。

The clinical observation of rabeprazole triple therapy for peptic ulcer

Objective To evaluate the efficacy of rabeprazote triple therapy for peptic ulcer. Methods 92 cases patients with peptic ulcer were Randomly divided into treatment group and control group, each of 46 cases. Treatment group were first given rabeprazole 10rag, amoxicillin 1.0g, clarithromyein 500rag; Control group were first given omeprazole 20rag, amoxicil lin 1.0g, clarithromycin 500rag ,2 times a day for 7d of two groups, 1 h taken before meals. Then treatment group were given rabeprazole separately 10rag, control group were given omeprazole 20mg,2 groups were daily, even for 7d. After treatment,compared ulcer healing rate, Helicobacter pylori （Hp） eradication rate of two groups, and observed adverse reaction of two groups. Results Ulcer healing rate of treatment group（ 91.30% ） was higher than that of control group（ 60.04% ） ,the difference was statistically significant（ P 〈 0. 01 ）. Adverse reaction of two groups were mild and may go away. Conclusion Rabeprazole based triple therapy regimens is an efficient, safe and economical method in the ulcer healing and Hp eradication.